What do we know about treatment sequencing of abiraterone, enzalutamide, and chemotherapy in metastatic castration-resistant prostate cancer?

World Journal of Urology

Volumn 34, Issue 5, 2016, Pages 617-624

  Lebdai, Souhil ^a   Basset, Victor ^b   Branchereau, Julien ^c   de La Taille, Alexandre ^d   Flamand, Vincent ^e   Lebret, Thierry ^f   Murez, Thibaut ^g   Neuzillet, Yann ^f   Ploussard, Guillaume ^b   Audenet, François ^h  

^a ANGERS UNIVERSITY HOSPITAL   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c HÔTEL DIEU   (France)

^d HENRI MONDOR HOSPITAL   (France)

^e LILLE UNIVERSITY HOSPITAL   (France)

^f LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^g LAPEYRONIE HOSPITAL   (France)

^h HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Abiraterone acetate; Cabazitaxel; Cross resistance; Docetaxel; Enzalutamide; Metastatic castration resistant prostate cancer; Therapeutic sequence

Indexed keywords

ABIRATERONE; ANDROSTANE DERIVATIVE; ANTINEOPLASTIC AGENT; CABAZITAXEL; DOCETAXEL; ENZALUTAMIDE; PHENYLTHIOHYDANTOIN; TAXOID;

ANALOGS AND DERIVATIVES; COMBINATION DRUG THERAPY; DRUG RESISTANCE; HUMAN; MALE; METASTASIS; PATHOLOGY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;

ANDROSTENES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG RESISTANCE, NEOPLASM; DRUG THERAPY, COMBINATION; HUMANS; MALE; NEOPLASM METASTASIS; PHENYLTHIOHYDANTOIN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TAXOIDS;

EID: 84941662425     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-015-1687-0     Document Type: Review

References (32)

1. de Bono JS, Logothetis CJ, Molina A et al (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364:1995–2005. doi:10.1056/NEJMoa1014618
2. Ryan CJ, Smith MR, Fizazi K et al (2015) Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 16:152–160. doi:10.1016/S1470-2045(14)71205-7
3. Scher HI, Fizazi K, Saad F et al (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367:1187–1197. doi:10.1056/NEJMoa1207506
4. Kantoff PW, Higano CS, Shore ND et al (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411–422. doi:10.1056/NEJMoa1001294
5. Parker C, Nilsson S, Heinrich D et al (2013) Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369:213–223. doi:10.1056/NEJMoa1213755
6. Tannock IF, de Wit R, Berry WR et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502–1512. doi:10.1056/NEJMoa040720
7. Mezynski J, Pezaro C, Bianchini D et al (2012) Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance? Ann Oncol 23:2943–2947. doi:10.1093/annonc/mds119
8. Schweizer MT, Zhou XC, Wang H et al (2014) The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer. Eur Urol 66:646–652. doi:10.1016/j.eururo.2014.01.018
9. Suzman DL, Luber B, Schweizer MT et al (2014) Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone. Prostate 74:1278–1285. doi:10.1002/pros.22844
10. Aggarwal R, Harris A, Formaker C et al (2014) Response to subsequent docetaxel in a patient cohort with metastatic castration-resistant prostate cancer after abiraterone acetate treatment. Clin Genitourin Cancer 12:e167–e172. doi:10.1016/j.clgc.2014.03.010
11. van Soest RJ, van Royen ME, de Morrée ES et al (2013) Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer. Eur J Cancer 49:3821–3830. doi:10.1016/j.ejca.2013.09.026
12. Azad AA, Leibowitz-Amit R, Eigl BJ et al (2014) A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer. Prostate 74:1544–1550. doi:10.1002/pros.22872
13. de Bono JS, Oudard S, Ozguroglu M et al (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376:1147–1154. doi:10.1016/S0140-6736(10)61389-X
14. Pezaro CJ, Omlin AG, Altavilla A et al (2013) Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents. Eur Urol 66:459–465. doi:10.1016/j.eururo.2013.11.044
15. Sella A, Sella T, Peer A et al (2014) Activity of cabazitaxel after docetaxel and abiraterone acetate therapy in patients with castration-resistant prostate cancer. Clin Genitourin Cancer 12:428–432. doi:10.1016/j.clgc.2014.06.007
16. Al Nakouzi N, Le Moulec S, Albigès L et al (2015) Cabazitaxel remains active in patients progressing after docetaxel followed by novel androgen receptor pathway targeted therapies. Eur Urol 68:228–235. doi:10.1016/j.eururo.2014.04.015
17. Sonpavde G, Bhor M, Hennessy D et al (2015) Sequencing of cabazitaxel and abiraterone acetate after docetaxel in metastatic castration-resistant prostate cancer: treatment patterns and clinical outcomes in multicenter community-based US oncology practices. Clin Genitourin Cancer 13(4):309–318, doi:10.1016/j.clgc.2014.12.019
18. Houts AC, Hennessy D, Walker MS et al (2014) Treatment patterns and clinical effectiveness in metastatic castrate resistant prostate cancer after first-line docetaxel. J Community Support Oncol 12:321–328. doi:10.12788/jcso.0072
19. Noonan KL, North S, Bitting RL et al (2013) Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. Ann Oncol 24:1802–1807. doi:10.1093/annonc/mdt138
20. Loriot Y, Bianchini D, Ileana E et al (2013) Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). Ann Oncol 24:1807–1812. doi:10.1093/annonc/mdt136
21. Schrader AJ, Boegemann M, Ohlmann C-H et al (2014) Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone. Eur Urol 65:30–36. doi:10.1016/j.eururo.2013.06.042
22. Thomsen FB, Røder MA, Rathenborg P et al (2014) Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate. Scand J Urol 48:268–275. doi:10.3109/21681805.2013.860189
23. Schmid SC, Geith A, Böker A et al (2014) Enzalutamide after docetaxel and abiraterone therapy in metastatic castration-resistant prostate cancer. Adv Ther 31:234–241. doi:10.1007/s12325-014-0092-1
24. Badrising S, van der Noort V, van Oort IM et al (2014) Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment. Cancer 120:968–975. doi:10.1002/cncr.28518
25. Brasso K, Thomsen FB, Schrader AJ et al (2014) Enzalutamide antitumour activity against metastatic castration-resistant prostate cancer previously treated with docetaxel and abiraterone: a multicentre analysis. Eur Urol. doi:10.1016/j.eururo.2014.07.028
26. Bianchini D, Lorente D, Rodriguez-Vida A et al (2014) Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone. Eur J Cancer 50:78–84. doi:10.1016/j.ejca.2013.08.020
27. Azad AA, Eigl BJ, Murray RN et al (2015) Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients. Eur Urol 67:23–29. doi:10.1016/j.eururo.2014.06.045
28. Hu R, Lu C, Mostaghel EA et al (2012) Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res 72:3457–3462. doi:10.1158/0008-5472.CAN-11-3892
29. Li Y, Chan SC, Brand LJ et al (2013) Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res 73:483–489. doi:10.1158/0008-5472.CAN-12-3630
30. Culig Z, Santer FR (2013) Molecular aspects of androgenic signaling and possible targets for therapeutic intervention in prostate cancer. Steroids 78:851–859. doi:10.1016/j.steroids.2013.04.012
31. Carver BS, Chapinski C, Wongvipat J et al (2011) Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 19:575–586. doi:10.1016/j.ccr.2011.04.008
32. Richards J, Lim AC, Hay CW et al (2012) Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100. Cancer Res 72:2176–2182. doi:10.1158/0008-5472.CAN-11-3980